3a,b, 4a,c, 5a,b, 6b,c, 8a,b in Oncogene 28(5):651–61, 2009; RT–PCR and/or ChIP experiments were included in six (6) of eight (8) figures in this publication.

Respondent has entered into a Voluntary Exclusion Agreement (Agreement). Respondent and the U.S. Public Health Service (PHS) want to conclude this matter without further expenditure of time or other resources. Respondent accepts ORI’s findings of research misconduct as set forth above but neither admits nor denies committing research misconduct. The Agreement does not constitute an admission of liability on Respondent’s part. Respondent agrees not to appeal the jurisdiction of ORI or request a U.S. Department of Health and Human Services (HHS) administrative hearing to review the findings as set forth in the Agreement.


In entering into the Agreement, Dr. Wang has voluntarily agreed for a period of two (2) years, beginning on July 18, 2011:

(1) To exclude himself from any contracting or subcontracting with any agency of the United States Government and from eligibility or involvement in nonprocurement programs of the United States Government referred to as “covered transactions” pursuant to HHS’ Implementation (2 CFR part 376 et seq) of OMB Guidelines to Agencies on Governmentwide Debarment and Suspension, 2 CFR part 180 (collectively the “Debarment Regulations”); and

(2) To exclude himself from serving in any advisory capacity to PHS, including but not limited to service on any PHS advisory committee, board, and/or peer review committee, or as a consultant.

FOR FURTHER INFORMATION CONTACT:
Director, Division of Investigative Oversight, Office of Research Integrity, 1101 Wootton Parkway, Suite 750, Rockville, MD 20852, (240) 453–8800.

John Dahlberg,
Director, Division of Investigative Oversight, Office of Research Integrity.

DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
Advisory Committee on Breast Cancer in Young Women (ACBCYW)

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92–463), the Centers for Disease Control and Prevention (CDC), announces the following meeting of the aforementioned committee:

**Times and Dates**
- 9 a.m.–5 p.m., September 21, 2011.
- 8 a.m.–4:30 p.m., September 22, 2011.
- 8 a.m.–2:30 p.m., September 23, 2011.

**Place:** CDC, Building 19, Auditorium B, Tom Harkin Global Communications Center, 1600 Clifton Road, NE., Atlanta, Georgia 30333.

**Status:** Open to the public, limited only by the space available.

**Purpose:** The committee provides advice and guidance to the Secretary, HHS; the Assistant Secretary for Health; and the Director, CDC, regarding the formative research, development, implementation and evaluation of evidence-based activities designed to prevent breast cancer (particularly among those at heightened risk) and promote the early detection and support of young women who develop the disease. The advice provided by the Committee will assist in ensuring scientific quality, timeliness, utility, and dissemination of credible appropriate messages and resource materials.

**Matters to Be Discussed:** The agenda will include discussions on health communications tools and resources related to breast cancer in young women including appropriate versus inappropriate messages for increased risk for developing breast cancer at younger ages; and approaches to increase awareness of clinicians/practitioners regarding topics such as breast health, symptoms, diagnosis, and treatment of breast cancer in young women.

Agenda items are subject to change as priorities dictate.

**Online Registration Required:** In order to expedite the security clearance process required for entry into a Federal building, all ACBCYW attendees must register for the meeting online at least 21 days in advance at http://www.cdc.gov/cancer/breast/what_cdc_is_doing/meetings.htm. Please complete all the required fields before submitting your registration and submit no later than August 29, 2011. Each meeting day, attendees must provide CDC staff and security with a driver’s license/state issued identification, or passport.

**Contact Person for More Information:** Temeska L. Fairfax, PhD, Designated Federal Officer, National Center for Chronic Disease Prevention and Health Promotion, CDC, 5770 Buford Highway, NE., Mallistop K52, Atlanta, Georgia 30341, Telephone: (770) 488–4518, Fax: (770) 488–4760.

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**
Centers for Disease Control and Prevention
Advisory Board on Radiation and Worker Health (ABRWH or Advisory Board), National Institute for Occupational Safety and Health (NIOSH)

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92–463), and pursuant to the requirements of 42 CFR 83.15(a), the Centers for Disease Control and Prevention (CDC), announces the following meeting of the aforementioned committee:

**Board Public Meeting Times and Dates (All times are Pacific Time):**
- 8:15 a.m.–5 p.m., August 23, 2011.
- 8:15 a.m.–4:45 p.m., August 24, 2011.
- 8:15 a.m.–12:30 p.m., August 25, 2011.

**Public Comment Times and Dates (All times are Pacific Time):**
- 5 p.m.–6 p.m.*, August 23, 2011.
- 5 p.m.–6:30 p.m.*, August 24, 2011.

*Please note that the public comment periods may end before the times indicated, following the last call for comments.

Members of the public who wish to provide public comments should plan to attend public comment sessions at the start times listed.

**Place:** Courtyard by Marriott, 480 Columbia Point, Richland, Washington 99352, Telephone: (509) 942–9400, Fax: (509) 942–9401.

Audio Conference Call via FTS Conferencing. The USA toll-free, dial-in number is 1–866–659–0537 with a pass code of 9933701.

**Status:** Open to the public, limited only by the space available. The meeting space accommodates approximately 150 people.

**Background:** The Advisory Board was established under the Energy Employees Occupational Illness Compensation Program Act of 2000 to advise the President on a variety of policy and technical functions required to implement and effectively manage the new compensation program. Key functions of the Advisory Board include providing advice on the development of probability of causation guidelines which have been promulgated by the Department of